NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

疤痕 - 流行病學考察:2030年

Scars - Epidemiology Insight - 2030

出版商 DelveInsight Business Research LLP 商品編碼 966818
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
疤痕 - 流行病學考察:2030年 Scars - Epidemiology Insight - 2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

本報告提供疤痕調查分析,過去、未來的流行病學,以美國、歐洲5個國家 (德國,西班牙,義大利,法國,英國) 、日本的市場趨勢為焦點,提供治療流程、治療指南,流行病學方案相關的系統性資訊。

目錄

第1章 主要考察

第2章 疤痕的摘要整理

第3章 疤痕:疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理生理學
  • 危險因素
  • 診斷

第4章 病人歷程

第5章 流行病學和患者族群

  • 流行病學的主要調查結果
  • 前提條件與根據:主要7個國家
  • 流行病學方案:主要7個國家
  • 美國的流行病學
  • 歐洲5個國家的各國流行病學
  • 日本的流行病學

第6章 治療流程,目前治療,醫療行為

  • 疤痕治療與管理
  • 疤痕治療演算法

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1093

DelveInsight's 'Scars - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Scars epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Scars Understanding

The DelveInsight Scars epidemiology report gives a thorough understanding of the Scars by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Scars in the US, Europe, and Japan. The report covers the detailed information of the Scars epidemiology scenario in seven major countries (US, EU5, and Japan).

Scars Epidemiology Perspective by DelveInsight

The Scars epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Scars epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Scars epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Scars Detailed Epidemiology Segmentation

The Scars epidemiology covered in the report provides historical as well as forecasted Scars epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Scars report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Scars report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Scars Epidemiology Report and Model provide an overview of the risk factors and global trends of Scars in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Scars in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Scars
  • The report provides the segmentation of the Scars epidemiology

Report Highlights:

  • 11-Year Forecast of Scars epidemiology
  • 7MM Coverage
  • Total Cases of Scars
  • Total Cases of Scars according to segmentation
  • Diagnosed cases of Scars

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Scars ?
  • What are the key findings pertaining to the Scars epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Scars across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Scars ?
  • What are the currently available treatments of Scars ?

Reasons to buy:

  • The Scars Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Scars market
  • Quantify patient populations in the global Scars market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Scars therapeutics in each of the markets covered
  • Understand the magnitude of Scars population by its epidemiology
  • The Scars Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Scars

3. Scars : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Scars Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Scars Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Scars Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Scars Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Scars Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Scars Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Scars Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Scars Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Scars Treatment and Management
  • 6.2. Scars Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Scars Epidemiology in 7MM (2017-2030)
  • Table 2: Scars Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Scars Epidemiology in the United States (2017-2030)
  • Table 4: Scars Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Scars Epidemiology in Germany (2017-2030)
  • Table 6: Scars Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Scars Epidemiology in France (2017-2030)
  • Table 8: Scars Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Scars Epidemiology in Italy (2017-2030)
  • Table 10: Scars Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Scars Epidemiology in Spain (2017-2030)
  • Table 12: Scars Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Scars Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Scars Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Scars Epidemiology in Japan (2017-2030)
  • Table 16: Scars Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Scars Epidemiology in 7MM (2017-2030)
  • Figure 2: Scars Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Scars Epidemiology in the United States (2017-2030)
  • Figure 4: Scars Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Scars Epidemiology in Germany (2017-2030)
  • Figure 6: Scars Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Scars Epidemiology in France (2017-2030)
  • Figure 8: Scars Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Scars Epidemiology in Italy (2017-2030)
  • Figure 10: Scars Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Scars Epidemiology in Spain (2017-2030)
  • Figure 12: Scars Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Scars Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Scars Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Scars Epidemiology in Japan (2017-2030)
  • Figure 16: Scars Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report